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Altered Platelet Function in Patients with Severe Congestive
Heart Failure*
Syed M. Jafri, MD,+ Jeanne M. Riddle, PhD,* Sundara B.K. Raman, MD,^
and Sidney Goldstein, MD'I

Platelet function was assessed in 15 patients with severe congestive heart failure (CHF) and in 26
control subjects of similar ages. The platelet count (mm'), surface reactivity, aggregometry studies,
release factors, and circulating aggregates were investigated. The mean number of circulating
platelets was normal, but a hyperactive platelet response was found in 53% ofthe CHF patients. CHF
patients had a 42% mean for the spread type platelet, and the average number of aggregates was 64:
control subjects had a 12% mean for the spread type platelet, and the average number of aggregates
was 40 (p < 0.05). Aggregation with all ofthe inducers was normal, aUhough 27% of CHF patients
showed spontaneous aggregation. The mean plasma levels of both platelet factor 4 and betathromboglobulin were abnormally elevated. No circulating platelet aggregates were detected. Our
studies indicate that platelet function is abnormal in patients with CHF. The abnormal platelet
reactivity found might contribute to the increased incidence of thromboembolic events ob.'ierved in
CHF patients. (Henry Ford Hosp Med J 1986:34:156-9)

T

hromboembolism is an important cause of morbidity and
mortality in patients with congestive heart failure (I). The
pathophysiologic mechanisms responsible for these events are
not clearly delineated. An increased incidence of thromboembolic episodes was observed in patients with larger cardiothoracic ratios and in those with chronic atrial fibrillation (2).
Because of the established association between congestive heart
failure and thromboembolism as well as the accepted role of
blood platelets in the formation of a thrombus (3), we studied the
platelet response of 15 patients with severe congestive heart
failure. Their results were compared to data obtained for controls of similar ages.
Scant information is available regarding platelet function in
patients with heart failure (4). The objective of our study was to
determine i f platelet function was normal or abnormal in a group
of patients with severe congestive heart failure.

Materials and Methods
Patient information
Fifteen patients, 11 men and four women, with chronic congestive heart failure (New York Heart Association funcdonal
class I I I to IV) whose mean age was 61 years (range 42 to 78
years) were included in the study. The etiology for heart failure
was coronary artery disease in ten patients and cardiomyopathy
in the other five patients. Two patients had a history of thromboembolic events, one of whom showed atrial fibrillation. Patients selected for this study did not have hypertension, a recent
acute myocardial infarction, a recent cerebrovascular accident,
unstable angina, primary valvular disease, or significant hepatic
or renal dysfunction.
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Six study patients received either a single antiplatelet agent or
two platelet-active agents. The antithrombotic agents used were
aspirin (1), heparin subcutaneously (3), andibuprofen (2). Blood
samples obtained from the heart failure patients were drawn
through an indwelling arterial catheter
Control groups
Two groups of control subjects were used to establish our normal values. Data for evaluation of surface reactivity and aggregation using electron microscopy, platelet release factors including platelet factor 4 and beta-thromboglobulin, platelet
count/mm\ as well as the platelet aggregate ratio were obtained
from 26 asymptomatic subjects who came to a general medical
clinic for a routine physical examination. This group's mean age
was 60 years (range 42 to 77 years), which was not significantly
different from the mean age of our heart failure patients. These
control subjects, 19 men and seven women, did not have any disease processes that produced recognizable clinical symptoms,
and none were on any dmgs known to alter platelet function.
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Normal values for the platelet aggregation studies were established from data collected on 50 asymptomatic subjects of
various ages. For the controls, peripheral blood was drawn by a
venipuncture using a siliconized butterfly infusion set and a 21gauge needle.
Platelet count
The number of circulating platelets (platelet count/mm') was
determined by using platelet-rich plasma obtained from whole
blood anticoagulated with ethylenediamine tetraaceric acid
(EDTA) processed in a Thrombo-fuge (Coulter Electronics, Inc,
Hialeah, FL). The platelet-rich plasma was diluted with Isoton II
and evaluated with a Coulter Counter, Model ZBl.
Platelet electron microscopic survey
Our standardized in vitro method (5) provided a morphologic
assessment of three separate phases of the platelet response:
adhesion, surface activation, and aggregadon. The platelets'
morphologic states were evaluated at the magnification and resolution capability ofthe transmission electron microscope. Three
distinct types of platelets were observed: round, dendritic, and
spread types. A platelet differential count included the percent
of round, dendritic, and spread types of platelets found on examination of 100 single platelets. The numberof platelet aggregates
seen during evaluation of these platelets was also determined.
Based on the limits of our control data ( ± two standard deviations), a hyperactive platelet response was defined as greater
than 36% of the spread type platelet and/or more than 94 aggregates/100 single platelets counted.
Platelet aggregometry
Aggregometry studies were performed with a Bio-Data Aggregadon Profiler (PAP-4, Biodata Corp, Philadelphia, PA)
using platelet-rich plasma (250 X lO** platelets/L) in combination with the following stimulants: epinephrine, adenosine diphosphate (ADP), collagen, and arachidonic acid. Specimens
that showed an aggregation rate of over 70% were tested for
spontaneous aggregation and were also studied using different
concentrations of the inducers.
Platelet aggregate ratio
The presence or absence of circulating platelet aggregates was
established according to the method of Wu and Hoak (6).
Platelet release factors
Plasma levels of the platelet release factors (platelet factor 4
and beta-thromboglobulin) were measured by radioimmunoassay methods (7).
Statistical analysis
The unpaired Student's t-test and chi-square test were used to
determine the level of significance for various tests of platelet
function. A p value of 0.05 or less was considered a significant
finding.
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Results
Platelet count/mm'
A comparison of the control subjects and the patients with
congestive heart failure showed that the number of circulating
platelets was within the normal range (126,000 to 450,000/mm')
at 257,000/mm\
Electron microscope differential count
Transmission electron microscopy demonstrated a stadstically significant (p < 0.05) decrease in the number of the
dendritic type platelet and a concomitant increase in the percent
of the spread type platelet in differential counts of patients with
congestive heart failure. The mean number of dendritic platelets
was 74% for the control group and 49% for the congestive heart
failure patients. In contrast, a mean value of only 12% of the
spread type platelet was found in the differential counts of the
control subjects, whereas the congestive heart failure patients
showed 42% of the spread type platelet (Figure) (p < 0.05).
A significantly increased mean number (p < 0.05) of platelet
aggregates (64 aggregates) was also noted for patients with congestive heart failure compared to the control subjects (40 aggregates). A hyperactive platelet response was found in three of 26
control subjects (12%) and in eight of 15 (53%) of the congestive
heart failure patients (p < 0.05). Therefore, the surface reactivity and/or aggregation of over half of the patients with congestive heart failure were abnormally increased.
Platelet aggregate ratio
The mean platelet aggregate ratio of 0,74 found in our control
subjects was not significantly different from the average rado
found for the patients with congestive heart failure (Table 1).
Platelet aggregometry
Evaluation of platelet aggregation induced by the various
stimulants for the entire group of patients with congestive heart
failure did not show any significant changes (Table 2). However,
platelets from four of the 15 padents (27%) aggregated spontaneously. In contrast, platelets removed fromfiveother patients
showed a release-type defect with two or more inducers. All of
these padents had received drugs known to inhibit platelet activity, primarily aspirin and ibuprofen.
Platelet release factors
The mean levels of both platelet factor 4 and beta-thromboglobulin were uniformly increased (p < 0.05) (Table 2). Nine
patients (60%) had an increased level of platelet factor 4, and 13
patients (87%) had an abnormal plasma concentration of betathromboglobulin.
Subgroup analysis
Subgroups of patients with conditions known to alter platelet
function, such as gout and diabetes mellitus, and patients who
received antiplatelet agents were analyzed separately. Data collected from patients with coronary artery disease were compared to results obtained from patients with cardiomyopathy.
Results of all the platelet function tests were not significantly
different in the subgroups compared to patients with congestive
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Table 1
Tests of Platelet Function
Platelet count ( X IOOO)
Electron microscope differential count
Round type (%)
Dendritic type (%)
Spread type (%)
Platelet aggregates (n)
Platelet aggregate ratio

Table 2
Platelet Aggregation and Release Factors

Controls

CHF

288 ± 162

257 ± 184

14
74
12
40
0.74

+
±
±
±
±

28
36
24
54
0.38

9
49*
42*
64*
0.87

±
±
±
±
±

18
58
64
126
0.54

*p < 0.05 between control subjects and CHF patients.
CHF = congestive heart failure.

heart failure who did not have a platelet-modifying state. The
platelet abnormalities were independent of whether the underlying etiology for the congestive heart failure was coronary artery
disease or cardiomyopathy (Table 3).

Discussion
Clinically recognized thromboembolism in patients with congestive heart failure reportedly occurs at a frequency of 15% to
20% (1,2). Evidence of either arterial or pulmonary emboli was
found in 22% of patients with dilated cardiomyopathy at autopsy
and in 18% by clinical examination of the survivors. Enlarged
cardiac size and atrial fibrillation conelated with a higher incidence of thromboembolic episodes (2).

Controls
Aggregometry
ADP (%)
Epinephrine (%)
Collagen (%)
Arachidonic acid (%)
Release factors
Platelet factor (ng/mL)
Beta-thromboglobulin (ng/mL)

5i)
50
50
50
7.51
42.93

8
X
8
8
-+-

±

CHF
57
51
52
52

±

±
±

30
4S
44
36

5.72
21.06*
22.48
.34.64 126.97* + 83.22

*p < 0.05 between control subjects and CHF patients.
CHF = congestive heart failure.

Limited information is cunentiy available regarding platelet
function in patients with congestive heart failure (4). Our investigation included tests that measured both the early stage (adhesion and surface activation) and later stage (aggregation and
release of platelet-specific proteins) of the platelet response.
Abnormalities of platelet function shown in our study were not
reported previously in these patients. Using electron microscopy, we found hyperactive platelets expressed as an abnormally increased number of the spread type platelet which is
an early feature of platelet activation. The cohesive capacity of
the platelets, demonstrated by their ability to form aggregates,
was also evaluated in the procedure which utilized the transmission electron microscope. The average number of aggregates
counted during the classification of 100 single platelets was sig-

Figure—A spread type platelet (arrow) and two platelet aggregates seen during a differential count on a patient with
congestive heart failure (X5,600).
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nificantly increased in the differential counts of the patients with
congestive heart failure. Advantages of our platelet electron microscopic survey over routine platelet aggregometry include
direct evaluation of the early stages of platelet activation and
assessment of the overall aggregability of a platelet population.
During the procedure the platelets are maintained in a compatible environment of anticoagulated whole blood and are not subjected to extensive manipulation such as the shear forces of
centrifugation.
Routine aggregometry which incorporates a centrifugation
step, however, also showed abnormalities of the platelet function
in blood samples removed from these patients. In 27% of the
congestive heart failure patients (four of 15 patients), the prepared platelet-rich plasma aggregated spontaneously without an
additional in vitro chemical inducer. The remaining patients
showed either a normal amount of aggregation (seven of 15 patients) or diminished aggregation, which was probably related to
recent ingestion of agents known to inhibit platelet function
(four of 15 padents).
Plasma levels of platelet release factors, platelet factor 4 and
beta-thromboglobulin, measures of in vivo platelet activation,
were also abnormally increased (8,9).
We did not find circulating platelet aggregates in the blood of
these patients. Our results conflict with an earlier study in which
platelet aggregates were demonstrated in the circulation of some
patients with congestive heart failure (4), We suspect that this
discrepancy may be explained by differences in the group of
control subjects used to establish the normal values in the two
investigations. Our control group consisted of healthy subjects
of similar ages, while the previous study used young volunteers
(mean age of 32 years). The mean value for our platelet aggregate rado was 0.74 rather than 0.91 which was reported in the
other study (4). The lower ratio thus changed the interpretation
of whether circulating aggregates were present.
Ourfindingsshow evidence of altered platelet function in patients with severe congestive heart failure. While the exact
mechanisms responsible for these abnormalities require further clarification, changes secondary to hemodynamic and neurohormonal alterations could be important. Activation of the
circulating platelets might occur in relation to the following hemodynamic alterations: 1) stasis due to a low cardiac output
state, or turbulence from valvular insufficiency because of dilated cardiac chambers; or 2) release of vasoactive substances
because of increased peripheral vascular resistance, Leyels of
norepinephrine (10), renin-angiotensin (11), and prostaglandin
12 and E2 (12) are frequendy increased in heart failure patients.
Elevated catecholamine levels previously have been associated
with platelet activation and hyperaggregation in a variety of conditions such as acute myocardial infarction (13) and mitral valve
prolapse (14),
Our study demonstrates that the platelet response is frequently abnormal in patients with congestive heart failure. The
altered platelet function is independent of associated plateletmodifying diseases and is consistent whether the etiology of the
congestive heart failure is coronary artery disease or cardiomyopathy. The increased platelet reactivity may directly
contribute to the high incidence of thromboembolism seen
clinically in these patients.
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Table 3
Subgroup Analysis of CHF Patients
ETIOLOGY OF CHF ANTI-PLATELET DRUGS
CAD
CM
Yes
No
Platelet count ( X 1000)
Surface activation
% Spread type
Total aggregates
Aggregometry
ADP
Epinephrine
Collagen
Arachidonic acid
Release faclors
Platelet factor 4
Beta-thromboglobulin
Platelet aggregate ratio
No. of patients

247

277

238

279

52
65

20
61

51
72

31
54

59
54
58
56

52
45
^0
45

48
37
39
44

ill

21.22
129.66
0.83
10

20.74
121.60
0.96
5

20.15
135.65
0.79
6

67
66

!:.!
22.10
117.06
0.97
9

CAD = coronary artery disease.
CM — cardiomyopathy.
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